
In the VAXAK trial, HPV vaccination significantly reduced the burden of actinic keratosis (AK) in immunocompetent adults with multiple lesions, showing a higher percentage reduction in AKs over 12 months compared to a sham vaccine. The vaccine also reduced the number of thick AKs. These findings suggest that HPV vaccines may be beneficial in managing AK, a common precursor to skin cancer.
Like
Save
Share